| scholarly article | Q13442814 |
| P356 | DOI | 10.1136/ARD.2008.092171 |
| P698 | PubMed publication ID | 18635596 |
| P2093 | author name string | M Roest | |
| F H J van den Hoogen | |||
| T R D J Radstake | |||
| P L C M van Riel | |||
| M G Netea | |||
| P Barrera | |||
| C Popa | |||
| A F H Stalenhoef | |||
| H L M Lemmers | |||
| L J H van Tits | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | TNF | Q18032037 |
| rheumatoid arthritis | Q187255 | ||
| lipoprotein | Q28350 | ||
| inflammation | Q101991 | ||
| P304 | page(s) | 868-872 | |
| P577 | publication date | 2008-07-17 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients | |
| P478 | volume | 68 |
| Q37728928 | A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis |
| Q33687843 | Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis |
| Q34348277 | Anti-TNFα therapy transiently improves high density lipoprotein cholesterol levels and microvascular endothelial function in patients with rheumatoid arthritis: a pilot study. |
| Q51421445 | Anti-arthritic effect of GN1, a novel synthetic analog of glucosamine, in the collagen-induced arthritis model in rats. |
| Q41143656 | Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritis |
| Q48752916 | Antibodies to high-density lipoproteins are associated with inflammation and cardiovascular disease in rheumatoid arthritis patients |
| Q41115717 | Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit |
| Q38293518 | Antisense oligonucleotides, microRNAs, and antibodies. |
| Q35541874 | Association of paraoxonase 1 gene polymorphism and enzyme activity with carotid plaque in rheumatoid arthritis. |
| Q36238859 | Atherogenic index and high-density lipoprotein cholesterol as cardiovascular risk determinants in rheumatoid arthritis: the impact of therapy with biologicals |
| Q41645180 | Atherosclerosis in rheumatoid arthritis |
| Q88917533 | Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis |
| Q34638027 | Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives |
| Q34563216 | Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment |
| Q38115132 | Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm |
| Q36190844 | Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. |
| Q37728019 | Clinical application and evaluation of anti-TNF-alpha agents for the treatment of rheumatoid arthritis |
| Q36830958 | Correlation of Paraoxonase Status with Disease Activity Score and Systemic Inflammation in Rheumatoid Arthritic Patients |
| Q57476499 | Correlation of Paraoxonase-1 with the Severity of Crohn's Disease |
| Q37637193 | Does a lack of physical activity explain the rheumatoid arthritis lipid profile? |
| Q35029916 | Dyslipidaemia in rheumatological autoimmune diseases |
| Q38166661 | Effect of treating psoriasis on cardiovascular co-morbidities: focus on TNF inhibitors |
| Q26748085 | Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist |
| Q41868896 | Enhanced cardiovascular risk in rheumatoid arthritis: elucidation, assessment, and management |
| Q51163456 | Epigenetic patterns of two gene promoters (TNF-α and PON) in stroke considering obesity condition and dietary intake. |
| Q36245981 | High-density lipoprotein cholesterol subfractions HDL2 and HDL3 are reduced in women with rheumatoid arthritis and may augment the cardiovascular risk of women with RA: a cross-sectional study |
| Q42848291 | High-density lipoprotein proteome dynamics in human endotoxemia. |
| Q37612713 | IL-32 promoter SNP rs4786370 predisposes to modified lipoprotein profiles in patients with rheumatoid arthritis |
| Q41914520 | Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial |
| Q52312175 | Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. |
| Q33891946 | Inflammation, lipid metabolism and cardiovascular risk in rheumatoid arthritis: A qualitative relationship? |
| Q46598130 | Infliximab, a TNF-α inhibitor, reduces 24-h ambulatory blood pressure in rheumatoid arthritis patients |
| Q37947514 | Interleukin-23 as a potential therapeutic target for rheumatoid arthritis |
| Q57307050 | Investigation of aPON1gene polymorphism (rs662 polymorphism) as predictor of subclinical atherosclerosis in patients with rheumatoid arthritis: Table 1 |
| Q26746659 | Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritis |
| Q38181566 | Lipid profile changes in patients with rheumatic diseases receiving a treatment with TNF-α blockers: a meta-analysis of prospective studies |
| Q37879605 | Necrotic cell death in atherosclerosis. |
| Q33898495 | Paraoxonase 1 polymorphism Q192R affects the pro-inflammatory cytokine TNF-alpha in healthy males |
| Q35899148 | Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis |
| Q59781603 | Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study |
| Q34153073 | Rationale of using different biological therapies in rheumatoid arthritis |
| Q37472928 | Role for TNF in atherosclerosis? Lessons from autoimmune disease |
| Q50318500 | Serum Lipid Alterations in Early Rheumatoid Arthritis Patients on Disease Modifying Anti Rheumatoid Therapy |
| Q60955111 | The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases |
| Q50109832 | The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review |
| Q44293608 | Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis |
| Q35118364 | What is the future of targeted therapy in rheumatology: biologics or small molecules? |
Search more.